Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament - PubMed (original) (raw)
. 2008 Aug;14(8):SR15-22.
Affiliations
- PMID: 18668010
Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament
John H Halpern et al. Med Sci Monit. 2008 Aug.
Abstract
Background: Ayahuasca is a South American hallucinogenic tea used as a sacrament by the Santo Daime Church, other religions, and traditional peoples. A recent U.S. Supreme Court decision indicates religious ayahuasca use is protected, but little is known about health consequences for Americans.
Material/methods: 32 (out of 40) American members of one branch of the Santo Daime Church were interviewed providing demographic information, physical exam, drug use timeline, a variety of psychological measures, and data about childhood conduct disorder. Subjects were asked about extent of Church participation, what is liked least and most about ayahuasca, and what health benefits or harms they attribute to ayahuasca.
Results: Members usually attend services weekly (lifetime 269+/-314.7 ceremonies; range 20-1300). Physical exam and test scores revealed healthy subjects. Members claimed psychological and physical benefits from ayahuasca. 19 subjects met lifetime criteria for a psychiatric disorder, with 6 in partial remission, 13 in full remission, and 8 reporting induction of remission through Church participation. 24 subjects had drug or alcohol abuse or dependence histories with 22 in full remission, and all 5 with prior alcohol dependence describing Church participation as the turning point in their recovery.
Conclusions: Conclusions should not be extrapolated to hallucinogen abusers of the general public. For those who have religious need for ingesting ayahuasca, from a psychiatric and medical perspective, these pilot results substantiate some claims of benefit, especially if subjects interviewed fully reflect general membership. Further research is warranted with blinded raters, matched comparison groups, and other measures to overcome present study limitations.
Similar articles
- Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members.
Santos RG, Landeira-Fernandez J, Strassman RJ, Motta V, Cruz AP. Santos RG, et al. J Ethnopharmacol. 2007 Jul 25;112(3):507-13. doi: 10.1016/j.jep.2007.04.012. Epub 2007 Apr 25. J Ethnopharmacol. 2007. PMID: 17532158 Clinical Trial. - Psychological and cognitive effects of long-term peyote use among Native Americans.
Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG Jr. Halpern JH, et al. Biol Psychiatry. 2005 Oct 15;58(8):624-31. doi: 10.1016/j.biopsych.2005.06.038. Biol Psychiatry. 2005. PMID: 16271313 Clinical Trial. - Dimethyltryptamine (DMT): subjective effects and patterns of use among Australian recreational users.
Cakic V, Potkonyak J, Marshall A. Cakic V, et al. Drug Alcohol Depend. 2010 Sep 1;111(1-2):30-7. doi: 10.1016/j.drugalcdep.2010.03.015. Epub 2010 May 31. Drug Alcohol Depend. 2010. PMID: 20570058 - Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges.
McKenna DJ. McKenna DJ. Pharmacol Ther. 2004 May;102(2):111-29. doi: 10.1016/j.pharmthera.2004.03.002. Pharmacol Ther. 2004. PMID: 15163593 Review. - Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids.
Gable RS. Gable RS. Addiction. 2007 Jan;102(1):24-34. doi: 10.1111/j.1360-0443.2006.01652.x. Addiction. 2007. PMID: 17207120 Review.
Cited by
- The Shipibo Ceremonial Use of Ayahuasca to Promote Well-Being: An Observational Study.
Gonzalez D, Cantillo J, Perez I, Carvalho M, Aronovich A, Farre M, Feilding A, Obiols JE, Bouso JC. Gonzalez D, et al. Front Pharmacol. 2021 May 5;12:623923. doi: 10.3389/fphar.2021.623923. eCollection 2021. Front Pharmacol. 2021. PMID: 34025402 Free PMC article. - Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey.
Perkins D, Schubert V, Simonová H, Tófoli LF, Bouso JC, Horák M, Galvão-Coelho NL, Sarris J. Perkins D, et al. Front Pharmacol. 2021 Apr 21;12:623979. doi: 10.3389/fphar.2021.623979. eCollection 2021. Front Pharmacol. 2021. PMID: 33967757 Free PMC article. - Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits.
Domínguez-Clavé E, Soler J, Pascual JC, Elices M, Franquesa A, Valle M, Alvarez E, Riba J. Domínguez-Clavé E, et al. Psychopharmacology (Berl). 2019 Feb;236(2):573-580. doi: 10.1007/s00213-018-5085-3. Epub 2018 Nov 7. Psychopharmacology (Berl). 2019. PMID: 30406413 - Ayahuasca: Uses, Phytochemical and Biological Activities.
Estrella-Parra EA, Almanza-Pérez JC, Alarcón-Aguilar FJ. Estrella-Parra EA, et al. Nat Prod Bioprospect. 2019 Aug;9(4):251-265. doi: 10.1007/s13659-019-0210-5. Epub 2019 May 27. Nat Prod Bioprospect. 2019. PMID: 31134518 Free PMC article. Review. - Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?
Malcolm BJ, Lee KC. Malcolm BJ, et al. Ment Health Clin. 2018 Mar 23;7(1):39-45. doi: 10.9740/mhc.2017.01.039. eCollection 2017 Jan. Ment Health Clin. 2018. PMID: 29955496 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous